Search Results - "Gilberg, Frank"

Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer by HALLER, Daniel G, TABERNERO, Josep, MAROUN, Jean, DE BRAUD, Filippo, PRICE, Timothy, VAN CUTSEM, Eric, HILL, Mark, GILBERG, Frank, RITTWEGER, Karen, SCHMOLL, Hans-Joachim

“…This multicenter, randomized trial compared capecitabine plus oxaliplatin (XELOX) with bolus fluorouracil (FU) and folinic acid (FA) as adjuvant therapy for…”
Get full text

Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 trial by Dréno, Brigitte, Prof, Kunstfeld, Rainer, Prof, Hauschild, Axel, Prof, Fosko, Scott, Prof, Zloty, David, MD, Labeille, Bruno, MD, Grob, Jean-Jacques, Prof, Puig, Susana, MD, Gilberg, Frank, PhD, Bergström, Daniel, PhD, Page, Damian R, PhD, Rogers, Gary, MD, Schadendorf, Dirk, Prof

“…Summary Background Vismodegib, a first-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell carcinoma. Patients with…”
Get full text

Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis by Costabel, Ulrich, Albera, Carlo, Glassberg, Marilyn K, Lancaster, Lisa H, Wuyts, Wim A, Petzinger, Ute, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Noble, Paul W

“…Data from controlled clinical studies in patients with more advanced idiopathic pulmonary fibrosis (IPF) could inform clinical practice, but they are limited,…”
Get full text

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease by Maher, Toby M, Schiffman, Courtney, Kreuter, Michael, Moor, Catharina C, Nathan, Steven D, Axmann, Judit, Belloni, Paula, Bengus, Monica, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Wijsenbeek, Marlies S

“…Background Patients with interstitial lung disease (ILD) require regular physician visits and referral to specialist ILD clinics. Difficulties or delays in…”
Get full text

Potential Regional Differences for the Tolerability Profiles of Fluoropyrimidines by HOLLER, Daniel G, CASSIDY, Jim, BERTINO, Joseph R, DOUILLARD, Jean-Yves, GUSTAVSSON, Bengt G, MILANO, Gerard, O'CONNELL, Michael, RUSTUM, Youcef, TABERNERO, Josep, GILBERG, Frank, SIRZEN, Florin, TWELVES, Chris, CLARKE, Stephen J, CUNNINGHAM, David, VAN CUTSEM, Eric, HOFF, Paulo M, ROTHENBERG, Mace L, SALTZ, Leonard B, SCHMOLL, Hans-Joachim, ALLEGRA, Carmen

“…We conducted a retrospective analysis of safety data from randomized, single-agent fluoropyrimidine clinical trials (bolus fluorouracil/leucovorin [FU/LV] and…”
Get full text

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis by Molina-Molina, Maria, Kreuter, Michael, Cottin, Vincent, Corte, Tamera J., Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Axmann, Judit, Maher, Toby M.

“…Approximately 12–13% of patients with interstitial lung disease (ILD) are diagnosed with unclassifiable ILD (uILD), often despite thorough evaluation. A recent…”
Get full text

Long-term Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis Is Independent of Baseline Forced Vital Capacity by Noble, Paul, MD, Albera, Carlo, MD, Kirchgaessler, Klaus-Uwe, MD, Gilberg, Frank, PhD, Petzinger, Ute, MS, Costabel, Ulrich, MD

Get full text

Rationale and Design of VOYAGER: Long-term Outcomes of Faricimab and Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema in Clinical Practice by Guymer, Robyn, Bailey, Clare, Chaikitmongkol, Voraporn, Chakravarthy, Usha, Chaudhary, Varun, Finger, Robert P, Gallego-Pinazo, Roberto, Chuan, Adrian Koh Hock, Ishida, Susumu, Lövestam-Adrian, Monica, Parravano, Mariacristina, Luna Pinto, Jose D, Schmitz-Valckenberg, Steffen, Sheth, Veeral, Souied, Eric H, Chi, Gloria C, Gilberg, Frank, Glittenberg, Carl, Scheidl, Stefan, Bengus, Monica

“…To describe the rationale and design of the VOYAGER (NCT05476926) study, which aims to investigate the safety and effectiveness of faricimab and the Port…”
Get full text

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial by Maher, Toby M, Corte, Tamera J, Fischer, Aryeh, Kreuter, Michael, Lederer, David J, Molina-Molina, Maria, Axmann, Judit, Kirchgaessler, Klaus-Uwe, Samara, Katerina, Gilberg, Frank, Cottin, Vincent

“…At present, no approved pharmacotherapies are available for unclassifiable interstitial lung disease (ILD), which is characterised by progressive fibrosis of…”
Get full text

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis by Flaherty, Kevin R, Fell, Charlene D, Huggins, J Terrill, Nunes, Hilario, Sussman, Robert, Valenzuela, Claudia, Petzinger, Ute, Stauffer, John L, Gilberg, Frank, Bengus, Monica, Wijsenbeek, Marlies

“…We assessed safety and tolerability of treatment with pirfenidone (1602-2403 mg·day ) and nintedanib (200-300 mg·day ) in patients with idiopathic pulmonary…”
Get full text

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial by Behr, Jürgen, Nathan, Steven D, Wuyts, Wim A, Mogulkoc Bishop, Nesrin, Bouros, Demosthenes E, Antoniou, Katerina, Guiot, Julien, Kramer, Mordechai R, Kirchgaessler, Klaus-Uwe, Bengus, Monica, Gilberg, Frank, Perjesi, Andras, Harari, Sergio, Wells, Athol U

“…The benefit of sildenafil in patients with advanced idiopathic pulmonary fibrosis (IPF) at risk of poor outcomes from pulmonary hypertension, whether already…”
Get full text

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis by Glassberg, Marilyn K, Wijsenbeek, Marlies S, Gilberg, Frank, Petzinger, Ute, Kirchgaessler, Klaus-Uwe, Albera, Carlo

“…Dyspnoea is a frequent and debilitating symptom in patients with idiopathic pulmonary fibrosis (IPF) and is reported as the most important factor determining…”
Get full text

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer by Ducreux, Michel, Tabernero, Josep, Grothey, Axel, Arnold, Dirk, O'Dwyer, Peter J., Gilberg, Frank, Abbas, Alexander, Thakur, Meghna Das, Prizant, Hen, Irahara, Natsumi, Tahiri, Anila, Schmoll, Hans-Joachim, Van Cutsem, Eric, de Gramont, Aimery

“…MODUL is an adaptable, signal-seeking trial of biomarker-driven maintenance therapy following first-line induction treatment in patients with metastatic…”
Get full text

Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study – Rationale and study design by Behr, Jürgen, Nathan, Steven D., Harari, Sergio, Wuyts, Wim, Kirchgaessler, Klaus-Uwe, Bengus, Monica, Gilberg, Frank, Wells, Athol U.

“…Pulmonary hypertension (PH) is commonly observed in patients with advanced idiopathic pulmonary fibrosis (IPF). Despite the availability of therapies for both…”
Get full text

Primary results from the STARLINER study of disease behaviour in suspected ILD by Wijsenbeek, Marlies S., Bendstrup, Elisabeth, Valenzuela, Claudia, Henry, Michael T., Moor, Catharina, Jouneau, Stéphane, Fois, Alessandro, Moran, Onofre, Anees, Syed, Mirt, Mirela, Bengus, Monica, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Vancheri, Carlo

Get full text

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use by Kreuter, Michael, Maher, Toby M., Corte, Tamera J., Molina-Molina, Maria, Axmann, Judit, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Cottin, Vincent

“…Introduction There are currently no approved treatments solely for unclassifiable interstitial lung disease (uILD); however, a recent trial showed this…”
Get full text

Analysis of Patients With Idiopathic Pulmonary Fibrosis (IPF) With More Severe Lung Function Impairment Treated With Pirfenidone in Recap by Costabel, Ulrich, Albera, Carlo, Kirchgaessler, Klaus-Uwe, Gilberg, Frank, Petzinger, Ute, Noble, Paul

Get full text

Efficacy and Safety of Pirfenidone in Advanced Versus Non-Advanced Idiopathic Pulmonary Fibrosis: Post-Hoc Analysis of Six Clinical Studies by Behr, Jürgen, Nathan, Steven D., Costabel, Ulrich, Albera, Carlo, Wuyts, Wim A., Glassberg, Marilyn K., Haller, Harold, Alvaro, Giuseppe, Gilberg, Frank, Samara, Katerina, Lancaster, Lisa

“…Introduction In the European Union (EU), the indication for the antifibrotic pirfenidone prior to April 2023 did not include patients with advanced idiopathic…”
Get full text

Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study by Wijsenbeek, Marlies, Bendstrup, Elisabeth, Valenzuela, Claudia, Henry, Michael T., Moor, Catharina, Bengus, Monica, Perjesi, Andras, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Vancheri, Carlo

“…Background/Objectives This study will aim to characterise disease behaviour during the peri-diagnostic period in patients with suspected interstitial lung…”
Get full text

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation by Maher, Toby M, Lancaster, Lisa H, Jouneau, Stéphane, Morrison, Lake, Lederer, David J, Molina-Molina, Maria, Bendstrup, Elisabeth, Kirchgaessler, Klaus-Uwe, Gilberg, Frank, Axmann, Judit, Petzinger, Ute, Noble, Paul W

“…Methods RECAP (NCT00662038) was an open-label extension study, including individuals who had completed the double-blind, placebo-controlled trials of…”
Get full text